Relationship between B-type natriuretic peptide and short-term prognosis in nondiabetic patients with ST-segment elevation myocardial infarction

Objective To investigate the difference in the level of B-type natriuretic peptide(BNP) and relationship between BNP and short-term prognosis in the patients with ST-segment elevation myocardial infarction(STEMI). Methods The patients with STEMI [n=124, firstly being hospitalized and accepting coronary angiography(CAG)] were chosen from the Central Hospital of Xuzhou City, and according to the outcomes of ECG and CAG, they were divided into group A(n=53), group B(n=41) and group C(n=30), and other patients with normal CAG(n=30) were chosen as group D(control group). The level of BNP was compared among all groups. All patients were divided again, according to the level of BNP, into normal BNP group(100 ng/mL, n=36), mild-higher BNP group(100-400 ng/mL, n=61 group) and marked-higher BNP group(≥400 ng/mL, n=27). The incidence of major adverse cardiovascular events(MACE, including secondary heart failure, severe arrhythmia, post-infarction angina, relapse myocardial infarction and cardiac death) was compared among all groups within 6 months. Results The level of BNP showed a gradual decreasing trend [(305.17±112.63) pg/mL,(201.38±72.54) pg/mL,(157.43±79.18) pg/mL,(39.49±15.07) pg/mL] in group A, group B, group C and group D(P0.05). The comparison in MACE incidence showed that there was no statistical difference between normal BNP group and mild-higher BNP group(P0.05), and there was statistical difference among all other BNP groups(P0.05). The incidence of MACE showed an increasing trend in normal BNP group, mild-higher BNP group and marked-higher BNP group. Conclusion The level of BNP can be taken as a clinical index for reviewing the short-term prognosis in the patients with STEMI.